Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

Bristol-Myers Squibb (BMS)

Status: Withdrawn

Conditions: Renal Cell Carcinoma

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT02928263

CA209-780

Details and patient eligibility

About

A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis with metastatic renal cell carcinoma
• Prescription/administration of one of the IV or oral agents examined in the study

Exclusion criteria

• Patients with other primary cancer diagnosis before RCC diagnosis
• Patients with pregnancy or HIV/AIDS

Trial design

0 participants in 2 patient groups

Patients treated with IV agents

Description:

Metastatic renal cell carcinoma patients treated with IV agents

Treatment:

Other: Non-Interventional

Patients treated with oral agents

Description:

Metastatic renal cell carcinoma patients treated with oral agents

Treatment:

Other: Non-Interventional